Faculty Bibliography

BACKGROUND: To evaluate the safety and efficacy associated with the clinical use of a Q-switched neodymium:yttrium-aluminum-garnet (ND:YAG) laser for cataract removal. DESIGN: Multicenter, prospective, noncomparative case series. PARTICIPANTS/INTERVENTION: A total of 1000 consecutive eyes underwent cataract extraction with the photolysis Q-switched ND:YAG laser at 12 international clinical sites. MAIN OUTCOME MEASURES: Visual acuity improvement; total energy used; mean operative time for cataract removal; complications, both intraoperative and postoperative; with a minimum follow-up of 3 months. RESULTS: The mean values were visual acuity improvement from 20/70.2 to 20/24.4. Mean intraocular energy used was 5.65 J per case. Mean operative photolysis time among the surgeons was for up to +1 nuclear sclerosis, 2.15 minutes; up to +2 nuclear sclerosis, 4.8 minutes; and for up to +3 nuclear sclerosis, 9.8 minutes. Three cases were completed by intraocular lens implantation through the original sub-2-mm incision, using a prefolded, by dehydration, acrylic intraocular lens. Minor complications were encountered in 18 cases. CONCLUSIONS: These data suggest this photolysis laser technology may be a safe and effective alternative for cataract extraction in human eyes. By use of small clear cornea incisions, the ability to perform cataract extraction and intraocular lens implantation with incisions less than 2 mm has been shown for the first time

OBJECTIVE: To evaluate the safety and efficacy of a Q-switched neodymium:YAG (Nd:YAG) laser for removal of the human cataract. DESIGN: A multicenter, prospective, noncomparative study. PARTICIPANTS: A total of 100 consecutive eyes undergoing cataract extraction with the Dodick Photolysis, Q-switched Nd:YAG laser. MAIN OUTCOME MEASURE: Corneal endothelial cell loss, visual acuity improvement, intraocular pressure change, total intraocular energy used, and intraoperative and postoperative complications. RESULTS: The mean values were postoperative visual acuity improvement from 20/46.5 (0.43) to 20/26.6 (0.75), decrease in endothelial cell count of 177 cells/mm2 (7.55%), and intraocular energy used of 6.7 J. Minor complications were encountered in three cases. CONCLUSIONS: These data suggest that Dodick Photolysis may be a safe and effective new technology for cataract removal in human eyes. It appears to offer low intraocular energy and heat release, a clear-cornea incision less than 1.5 mm in size, and safe operation within the capsular bag

PURPOSE: The authors performed a prospective evaluation of the efficacy of treating ocular cicatricial pemphigoid (OCP) with subconjunctival mitomycin C. DESIGN: Unmasked, prospective, internally controlled case series. METHODS: Patients were eligible for treatment with subconjunctival mitomycin C under three criteria: (1) significant complications of systemic immunosuppressant therapy; (2) markedly asymmetric conjunctival disease; and (3) end-stage OCP. All patients received monocular subconjunctival injections of 0.25 ml of 0.2 mg/ml mitomycin C to both the superior and inferior bulbar conjunctivae in the eye with the more severe disease. RESULTS: Nine eyes of nine patients (mean age, 74 years) were treated with subconjunctival mitomycin C to the more-involved eye and were followed for a mean of 23.5 months (range, 12-40 months). Eight of nine patients showed quiescence of their OCP in the treated eye based on serial evaluation of conjunctival cicatrization and grading of conjunctival erythema. Five of the nine untreated eyes showed progression of the conjunctival disease. One patient required concomitant systemic immunosuppressive therapy after subconjunctival mitomycin C. Two patients underwent successful visual rehabilitative surgery in the mitomycin C-treated eye. CONCLUSION: The use of subconjunctival mitomycin C may be effective in preventing progression of conjunctival cicatrization and erythema in patients with OCP. No complications of mitomycin C treatment were noted. Long-term follow-up and further investigation into the efficacy of subconjunctival mitomycin C in the management of OCP is warranted

PURPOSE: To evaluate the effect on intraocular pressure (IOP) of substituting topical Cyclosporine A 0.5% for topical corticosteroids in patients with postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH). We also sought to determine the penetration of topical 0.5% Cyclosporine A into the cornea and anterior chamber. METHODS: Topical Cyclosporine A 0.5% was prospectively substituted for topical corticosteroids in 47 patients (52 eyes) with postkeratoplasty glaucoma and CIOH in order to eliminate the IOP-elevating effect of topical corticosteroids, while maintaining protection against allograft rejection. Ten patients received 0.5% topical Cyclosporine before keratoplasty. Their corneal tissue and aqueous samples were evaluated by high pressure liquid chromatography for Cyclosporine levels. RESULTS: Forty-eight of 52 eyes (92.3%) demonstrated a reduction of IOP at first followup (mean: -7.9 mmHg; range: -19 to +2). Mean followup was 10.3 months, ranging from 1 to 37 months. At last follow-up, mean IOP was -8.2 mm Hg. There were six allograft rejections, five of which were reversed with the reintroduction of topical corticosteroids. Graft clarity was maintained in 46 of 52 eyes (88%). The mean cornea Cyclosporine concentration was 3679 ng/gm (range: 1980 to 5520 ng/ gm) and aqueous humor mean concentration was 6.05 ng/mL (range: 0.4 to 15.5 ng/mL). CONCLUSIONS: Topical Cyclosporine A 0.5% may be substituted for topical corticosteroids to aid in the management of postkeratoplasty glaucoma and CIOH. However, the use of Cyclosporine in place of corticosteroids may be associated with an increased risk of immune rejections. The corneal penetration of topical Cyclosporine is excellent while the penetration into the anterior chamber is poor